Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZX008 in Lennox-Gastaut syndrome
NL-OMON48657Phase 3Active, not recruiting
- Sponsor
- Zogenix, Inc.
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fenfluramine in Lennox-Gastaut syndrome (LGS) and epilepsy (4 arms), sponsored by Zogenix, Inc. Primary endpoints: Change in frequency of seizures that result in drops, Number, frequency, and duration of countable seizures that result in drops and 1 more. Started Nov 2017; status: active, not recruiting.
02
Drugs
fenfluramine
03
Conditions
Lennox-Gastaut syndrome (LGS)epilepsy
Beyond the preview
Go deeper on NL-OMON48657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48657.